Concord Biotech IPO: Listing at 21.5% Premium & Future Plans Revealed!
Concord Biotech IPO: What is Concord Biotech's future plan, business model, listing at a premium of 21.5%? Where will the money raised from IPO be used? In conversation with Ankur Vaid, Joint MD & CEO, Concorde Biotech and Lalit Sethi, CFO
Written By: Zee Business Video Team